BenzingaOctober 13, 2026 at 10:05 AM NY14 Days Ago
Barclays Maintains Overweight on Xylem, Lowers Price Target to $139
Barclays analyst William Grippin maintains Xylem (NYSE:XYL) with a Overweight and lowers the price target from $159 to $139.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
